Seoul
Chief MD, Gangnam
Duk-ha Kim
The trust our patients have placed in this clinic was built on conviction and principle. We intend to hold to both, unchanged, through the next hundred years.
PDO filler guide
ULTRACOL 200
ULTRACOL 200 is an injectable filler whose main material is PDO (polydioxanone), made by the Korean manufacturer Ultra V. It is a different polymer from PLLA — the material in Sculptra — and the only peer-reviewed study specific to this product was formally retracted in November 2025.
- Core material
- PDO (polydioxanone) microspheres — maker states 50–110 µm particle size, 200 mg per vial
- Manufacturer
- Ultra V (South Korea)
- Peer-reviewed evidence
- The only product-specific study was formally retracted in November 2025
- Compared with Sculptra
- Different polymer class (PDO vs. PLLA); no head-to-head study published
What is ULTRACOL 200?
ULTRACOL 200 is an injectable filler product made by the Korean manufacturer Ultra V. Its product page describes the material as “PDO (Polydioxanone)” and calls it “the world’s first PDO-based product,” with a stated particle size of 50–110 µm and 200 mg of material per vial.
Sources: Ultra V — ULTRACOL product page (PDO microsphere, particle size and vial content)
What is PDO, and where else is it used?
PDO stands for polydioxanone, a biodegradable synthetic polymer long used to make absorbable surgical sutures. ULTRACOL 200 uses the same base polymer in microsphere form for injection rather than as thread.
Sources: Ultra V — ULTRACOL product page (PDO microsphere, particle size and vial content)
How is PDO chemically different from PLLA?
PDO and PLLA (poly-L-lactic acid) are separate polymer families. PDO comes from suture material; PLLA is a lactic-acid-based polymer used in products such as Sculptra. Because the two come from different chemical families, the properties of one should not be assumed for the other.
Sources: Ultra V — ULTRACOL product page (PDO microsphere, particle size and vial content)
Is ULTRACOL 200 the same treatment as Sculptra?
No. Sculptra’s labeled material is PLLA; ULTRACOL 200’s stated material is PDO. A shared marketing phrase such as “collagen stimulator” does not mean two products share the same base material, so the exact product name and material are worth confirming rather than assumed from a category label.
Sources: Ultra V — ULTRACOL product page (PDO microsphere, particle size and vial content)
Are all “collagen stimulator” injectables the same product?
No. The phrase “collagen stimulator” is used across several different materials, including PLLA and PDO, which come from different polymer families. Products advertised with the same phrase can have different active ingredients, so ask for the exact product name and material rather than relying on a category label.
Sources: Ultra V — ULTRACOL product page (PDO microsphere, particle size and vial content)
Has PDO ever been compared with PLLA in a study?
No peer-reviewed study directly comparing ULTRACOL 200 (PDO) with Sculptra (PLLA) has been published. Without that evidence, no claim is made here about which material lasts longer or performs better.
Sources: Ultra V — ULTRACOL product page (PDO microsphere, particle size and vial content)Skin Research and Technology 2025;31(11):e70286 — retraction notice for the ULTRACOL 200 nasolabial fold study
The manufacturer’s stated use for ULTRACOL 200
Ultra V’s product page states the material is “injected into areas with reduced elasticity and visible fine wrinkles.” Its corporate site separately describes the approved indication as the temporary improvement of nasolabial folds on both sides of the face. Both statements are the manufacturer’s own wording, from two different pages of its own materials.
Sources: Ultra V — ULTRACOL product page (PDO microsphere, particle size and vial content)Ultra V — corporate site stating the Korean manufacturing licence number and the approved indication wording
What manufacturing licence does the corporate site state?
Ultra V’s corporate site states a Korean medical-device manufacturing licence number for ULTRACOL 200, No. 20-598.
Is ULTRACOL 200 CE marked?
Ultra V’s corporate site states that ULTRACOL 200 carries CE marking obtained under the European Union’s medical device regulation.
Was there ever a peer-reviewed study on this specific product?
Yes — one. A 2024 study in Skin Research and Technology examined ULTRACOL 200 injected into the nasolabial fold in 31 participants, given twice four weeks apart in a split-face design and followed for eight weeks. It is the only product-specific peer-reviewed study on ULTRACOL 200, and it has since been retracted.
Why was that 2024 study retracted?
The journal’s official retraction notice, published in Skin Research and Technology in November 2025, gives three reasons: the peer review the article received did not meet the journal’s policies; the article lacked methodological detail needed to reproduce and interpret the results; and several co-authors, employed by the manufacturer of the study product, had not disclosed that financial relationship.
Where can you read the retraction notice yourself?
The retraction notice was published in Skin Research and Technology, volume 31, issue 11, article e70286, in November 2025. It is a short, publicly indexed document, so you can look up the same notice and read the journal’s three stated reasons in full rather than relying on a summary.
Why might ULTRACOL 200 be listed under another name?
Clinic menus and booking platforms sometimes group different “collagen-stimulating” injectables under one popular nickname, even when the underlying materials differ. If ULTRACOL 200 is described with wording usually associated with a PLLA-based product, ask the clinic to confirm the material and product name directly.
Sources: Ultra V — ULTRACOL product page (PDO microsphere, particle size and vial content)
How long does the effect last?
The only study that measured this product directly was retracted, so its outcome figures are not repeated here. What is left is the manufacturer’s own description: a PDO microsphere material, described as biodegradable, injected into areas with reduced elasticity and fine wrinkles. For a biodegradable microsphere filler, how long any visible change lasts is generally shaped by how much material was placed, the depth and technique of injection, the area treated, and each person’s own rate of breaking down the material — none of which is stated in the sources cited here for this specific product. Ask the clinic how many vials and sessions are planned, at what interval, and whether that plan is based on published evidence for this exact product or on experience with the PDO material generally.
Sources: Ultra V — ULTRACOL product page (PDO microsphere, particle size and vial content)Skin Research and Technology 2025;31(11):e70286 — retraction notice for the ULTRACOL 200 nasolabial fold study
What should you confirm before booking?
Ask to see the product box and confirm the exact name printed on it — ULTRACOL 200, not a nickname. Confirm the material is PDO, ask whether the clinic can show the manufacturer’s licence and CE documentation, and ask what peer-reviewed evidence, if any, currently supports the treatment plan being proposed. Bring your allergy and scar history, and confirm the injector’s training.
Sources: Ultra V — ULTRACOL product page (PDO microsphere, particle size and vial content)Ultra V — corporate site stating the Korean manufacturing licence number and the approved indication wording
Are PDO and PLLA interchangeable terms?
No — they name two different polymer materials sold in different products. Compare the stated material below rather than a shared marketing nickname.
| Product | Core material | Material origin | Peer-reviewed head-to-head study |
|---|---|---|---|
| ULTRACOL 200 | PDO (polydioxanone) microspheres, per maker | Absorbable-suture polymer | None published; this product’s only study was retracted in 2025 |
| Sculptra | PLLA (poly-L-lactic acid) microparticles | Lactic-acid-based polymer | None published comparing it against PDO |
This table compares stated materials only, not effectiveness, safety, or ranking.
Sources: Ultra V — ULTRACOL product page (PDO microsphere, particle size and vial content)Skin Research and Technology 2025;31(11):e70286 — retraction notice for the ULTRACOL 200 nasolabial fold study
Medical care at Abijou
Care is provided by the medical team at the branch you select. These clinicians lead the three branches linked from this guide; confirm the doctor assigned to your visit with that branch.
Chief MD, Myeongdong
Cheol-su Yoon
I want to be thinking about how the patient feels right up to the last moment of the procedure.
Chief MD, Hongdae
Jae-wook Kim
I will give my best with the attentiveness to catch even the smallest change.
Listed branch medical team — not a medical-review byline for this article.
Frequently asked questions
Is ULTRACOL 200 the same product as Sculptra?
No. ULTRACOL 200’s main material is PDO (polydioxanone); Sculptra’s is PLLA (poly-L-lactic acid). They are different polymer families, and no peer-reviewed study comparing them head-to-head has been published.
What is PDO?
PDO stands for polydioxanone, a biodegradable synthetic polymer long used in absorbable surgical sutures. Ultra V describes ULTRACOL 200 as microspheres made from this material, with a stated particle size of 50–110 µm and 200 mg per vial.
Is ULTRACOL 200 the same as a “PLLA filler”?
No. Marketing terms like “collagen stimulator” are used across several different materials, including PLLA and PDO. ULTRACOL 200’s stated material is PDO, not PLLA, so it is not the same substance as a PLLA-based product such as Sculptra.
What does the manufacturer say ULTRACOL 200 treats?
Ultra V’s product page describes it as injected into areas with reduced elasticity and visible fine wrinkles. Its corporate site separately states the approved indication as the temporary improvement of nasolabial folds on both sides of the face.
Does ULTRACOL 200 have a Korean manufacturing licence?
Ultra V’s corporate site states a Korean medical-device manufacturing licence number for the product, No. 20-598.
Is ULTRACOL 200 CE marked?
Ultra V’s corporate site states that CE marking was obtained under the European Union’s medical device regulation.
Is there peer-reviewed evidence that ULTRACOL 200 works?
The only product-specific peer-reviewed study — a 2024 nasolabial-fold study in Skin Research and Technology — was formally retracted in November 2025.
Why was the 2024 ULTRACOL 200 study retracted?
The journal’s retraction notice cites three reasons: peer review that did not meet the journal’s policies, missing methodological detail needed to reproduce and interpret the results, and undisclosed financial conflicts of interest — several co-authors were employed by the product’s manufacturer.
What was the retracted study’s design?
It examined ULTRACOL 200 injected into the nasolabial fold in 31 participants, given twice at a four-week interval and followed for eight weeks in a split-face comparison.
Where can I read the retraction notice myself?
It was published in Skin Research and Technology, volume 31, issue 11, article e70286, in November 2025, and is indexed under that citation for anyone who wants to read the journal’s stated reasons directly.
Does the retraction notice say anything about the product’s safety?
No — its three stated reasons concern the peer-review process, missing methodological detail, and undisclosed author conflicts of interest. It does not include a separate safety finding.
Are all “collagen stimulator” injectables the same?
No. The term is used across different materials, including PLLA and PDO, which come from different polymer families. Ask for the exact product name and material rather than relying on a category label.
Why might ULTRACOL 200 be listed under another name?
Clinic menus sometimes group different “collagen-stimulating” injectables under one popular nickname, even when the underlying materials differ. Ask the clinic to confirm the material and product name directly rather than relying on a nickname.
What should I ask the clinic before booking ULTRACOL 200?
Ask to see the product box for the exact name, confirm the material is PDO, ask whether the clinic can show manufacturing-licence and CE documentation, and ask what peer-reviewed evidence, if any, currently supports the treatment plan being proposed.
How Abijou works
We started in Gangnam in 2006 and the network now runs 17 branches across Korea. The line we work to is skin transformation woven into everyday life — care you can keep up with, rather than one dramatic change.
- Across the 17 branches in Seoul, Gyeonggi, Incheon and Busan: over 1,000 medical professionals and more than 350 certified medical devices
- Authentic products only, in appropriate amounts — the treatment is fitted to the condition, not to a package
- Prices are quoted from each branch’s published price list as it stands
Contact and location
- Phone
- 1544-0377
Free Consultation
Booking happens at the branch
There is no inquiry form on this page. Once you have picked a branch above, open that branch’s site or the official reservation center and choose a time yourself.
- No deposit and no online prepayment — everything is paid at the visit
- Per-treatment prices are published for each branch on the official reservation center
- English, Japanese and Chinese are supported alongside Korean